

AHCL/ SE/ 7 /2022-23

May 24, 2022

<b>The National Stock Exchange of India Limited</b> "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	<b>BSE Limited</b> Department of Corporate Services 1 <sup>st</sup> Floor, P.J. Towers, Dalal Street, Mumbai 400 001
<b>Symbol : AMRUTANJAN</b>	<b>Scrip Code: 590006</b>

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting**

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today (**May 24, 2022**) had inter-alia:

- (i) Approved the Audited Financial Results for the quarter and year ended March 31, 2022, as recommended by the Audit Committee at its meeting held today (May 24 2022) The same along with the Independent Auditor's Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Recommended Final Dividend of Rs. 2.60 per equity share on 2,92,30,630 shares of Re. 1 each fully paid up for the financial year 2021-22. The Final dividend if approved at the Annual General Meeting will be paid to eligible shareholders within 30 days of AGM.

The Board Meeting commenced at 11.00 A.M. and concluded at 7.30 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited

(M Srinivasan)  
Company Secretary & Compliance Officer



**Encl:**

1. Audited Standalone Financials Results for the quarter and year ended March 31, 2022
2. Independent Auditor's Report for the quarter and year ended March 31, 2022
3. Declaration under Regulation 33 3(d) of SEBI LODR Regulations 2015.

**Amrutanjan Health Care Limited**

103, (Old No. 42-45), Luz Church Road,  
Mylapore, Chennai - 600 004  
Tamil Nadu, India.  
Tel :+91-44 - 2499 4465  
+91-44 - 2466 9000  
Fax :+91-44 - 2499 4585

E-mail : [customercare@amrutanjan.com](mailto:customercare@amrutanjan.com)  
Web Site : [www.amrutanjan.com](http://www.amrutanjan.com)  
Toll Free No. : 1 - 800 - 425 - 4545  
CIN - L24231TN1936PLC000017

**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Statement of Audited Financial Results for the quarter and year ended 31 March 2022**

(Rs.in Lakhs)

	Particulars	Quarter ended			Year ended	
		31 March 2022 (Audited - refer note 4)	31 December 2021 (Unaudited)	31 March 2021 (Audited - refer note 4)	31 March 2022 (Audited)	31 March 2021 (Audited)
I	Revenue from operations	10,655.30	11,069.59	9,401.68	40,584.24	33,284.40
II	Other income	516.02	319.83	268.10	1,538.25	1,132.01
III	<b>Total income (I + II)</b>	<b>11,171.32</b>	<b>11,389.42</b>	<b>9,669.78</b>	<b>42,122.49</b>	<b>34,416.41</b>
IV	<b>Expenses</b>					
	(a) Cost of materials consumed	3,446.13	3,004.76	2,278.90	12,186.02	8,705.95
	(b) Purchases of stock-in-trade	1,773.50	1,717.37	1,984.39	6,410.22	4,812.00
	(c) Changes in inventories of finished goods and stock-in-trade	(215.03)	(41.68)	(212.97)	(549.99)	500.57
	(d) Employee benefits expense	1,230.40	1,159.67	1,219.13	4,822.90	4,170.33
	(e) Advertisement and selling expenditure	856.31	1,972.35	1,859.47	5,503.26	4,598.94
	(f) Finance cost	30.08	2.98	36.71	48.45	50.00
	(g) Depreciation and amortisation expense	119.30	87.72	99.00	379.52	366.97
	(h) Other expenses	1,928.70	694.75	1,034.00	4,264.45	3,021.20
	<b>Total expenses (IV)</b>	<b>9,169.39</b>	<b>8,597.92</b>	<b>8,298.63</b>	<b>33,064.83</b>	<b>26,225.96</b>
V	<b>Profit before tax (III - IV)</b>	<b>2,001.93</b>	<b>2,791.50</b>	<b>1,371.15</b>	<b>9,057.66</b>	<b>8,190.45</b>
VI	Tax expenses	531.34	733.72	348.27	2,338.77	2,071.41
VII	<b>Profit after tax (V - VI)</b>	<b>1,470.59</b>	<b>2,057.78</b>	<b>1,022.88</b>	<b>6,718.89</b>	<b>6,119.04</b>
VIII	<b>Other comprehensive income</b>					
	Items that will not be reclassified subsequently to profit or loss					
	Re-measurement gain/(loss) on defined benefit plans, net of taxes	2.72	(24.24)	4.68	(63.84)	(2.80)
	<b>Other comprehensive income/ (loss) for the period, net of taxes</b>	<b>2.72</b>	<b>(24.24)</b>	<b>4.68</b>	<b>(63.84)</b>	<b>(2.80)</b>
IX	<b>Total comprehensive income for the period (VII + VIII)</b>	<b>1,473.31</b>	<b>2,033.54</b>	<b>1,027.56</b>	<b>6,655.05</b>	<b>6,116.24</b>
	Paid-up equity share capital (Face value Re. 1/- each)	292.31	292.31	292.31	292.31	292.31
	<b>Earnings per equity share for continuing operations</b>					
	Basic earnings per share (INR)	5.09	7.05	3.50	23.05	20.94
	Diluted earnings per share (INR)	5.08	7.03	3.50	23.03	20.93
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	<i>See accompanying notes to financial results</i>					



**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004  
**Statement of assets and liabilities**

		(Rs.in Lakhs)	
S. No.	Particulars	As at	As at
		31 March 2022	31 March 2021
		Audited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	2,651.87	2,176.89
	(b) Right-of-use assets	68.68	113.42
	(c) Intangible assets	124.91	36.28
	(d) Capital work in progress	1,626.49	41.39
	(e) Intangible assets under development	106.96	115.16
	(e) Financial assets		
	Investments	535.97	1,201.21
	Other financial assets	1,694.97	858.53
	(f) Tax assets	155.56	120.27
	(g) Deferred tax assets (net)	364.19	342.50
	(h) Other non-current assets	192.28	131.58
	<b>Total non-current assets</b>	<b>7,521.88</b>	<b>5,137.23</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	2,600.07	1,745.86
	(b) Financial assets		
	Investments	751.53	582.77
	Trade receivables	3,825.60	1,766.29
	Cash and cash equivalents	218.62	290.51
	Other bank balances	8,556.64	13,641.19
	Other financial assets	11,007.87	3,881.01
	(c) Other current assets	504.60	382.21
	<b>Total current assets</b>	<b>27,464.93</b>	<b>22,289.84</b>
	<b>Total assets (1+2)</b>	<b>34,986.81</b>	<b>27,427.07</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity share capital	292.31	292.31
	(b) Other equity	26,220.07	21,264.16
	<b>Total equity</b>	<b>26,512.38</b>	<b>21,556.47</b>
	<b>Liabilities</b>		
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Financial liabilities		
	Lease liabilities	31.06	70.28
	Other financial liabilities	16.60	17.60
	(b) Provisions	679.47	572.38
	<b>Total non-current liabilities</b>	<b>727.13</b>	<b>660.26</b>
<b>3</b>	<b>Current liabilities</b>		
	(a) Financial liabilities		
	Lease liabilities	56.93	63.96
	Trade payables		
	total outstanding dues of micro and small enterprises	557.02	218.23
	total outstanding dues of creditors other than micro and small enterprises	5,487.86	3,848.64
	Other financial liabilities	571.06	244.66
	(b) Other current liabilities	650.12	486.00
	(c) Provisions	424.31	348.85
	<b>Total current liabilities</b>	<b>7,747.30</b>	<b>5,210.34</b>
	<b>Total equity and liabilities (1+2+3)</b>	<b>34,986.81</b>	<b>27,427.07</b>



**AMRUTANJAN HEALTH CARE LIMITED**

CIN No : L24231TN1936PLC000017

Registered Office: No. 103 (Old No. 42-45), Luz Church Road

Mylapore, Chennai - 600 004

**Statement of Cash flows for the year ended 31 March 2022**

*(Rs. In Lakhs)*

Particulars	For the year ended March 31, 2022	For the year ended March 31, 2021
	Audited	Audited
<b>Cash flow from operating activities</b>		
Profit before income tax	9,057.66	8,190.45
Adjustments for:		
Depreciation and amortisation	379.52	366.97
Profit on sale of property, plant and equipment	-	(8.94)
Share based compensation expense	(1.13)	61.78
Loss allowance on trade receivables	39.87	159.77
Change in fair value of investments	15.71	36.66
Gain on sale of investments	(1.60)	-
Interest income on deposits with banks and financial institutions	(1,028.92)	(847.45)
Interest income on debt instruments	(88.07)	(91.39)
Excess provision written back, (net)	(389.88)	(17.28)
Finance costs	48.45	50.00
Unrealised gain on foreign exchange differences	-	(5.24)
<b>Operating profit before working capital / other changes</b>	<b>8,031.61</b>	<b>7,895.33</b>
Working capital adjustments:		
(Increase)/decrease in trade receivables	(2,099.18)	725.54
(Increase)/decrease in current and non current assets	(121.79)	318.25
(Increase)/Decrease in other financial assets	(4.54)	7.68
(Increase)/decrease in inventories	(854.21)	625.73
Increase in financial liabilities	135.15	68.15
Increase in provisions	118.04	15.39
Increase in trade payables	2,367.89	949.90
Increase in current liabilities	162.77	239.97
	<b>(295.87)</b>	<b>2,950.61</b>
<b>Cash generated from operating activities</b>	<b>7,735.74</b>	<b>10,845.94</b>
Less: Income tax paid (net)	(2,419.20)	(1,869.65)
<b>Net cash generated from operating activities (a)</b>	<b>5,316.54</b>	<b>8,976.29</b>
<b>Cash flow from investing activities</b>		
Purchase or construction of property, plant and equipment, intangible assets, capital work in progress, intangible assets under development	(2,346.34)	(196.07)
Proceeds from sale of Property, plant and equipment	-	8.94
Investment in bank deposits and financial institutions	(3,020.60)	(9,152.73)
Interest received on deposits with banks and financial institutions	1,155.03	492.51
Proceeds from sale of investments	482.36	-
Interest received on debt instruments	108.35	71.27
<b>Net cash used in investing activities (b)</b>	<b>(3,621.20)</b>	<b>(8,776.08)</b>
<b>Cash flow from financing activities</b>		
Dividend paid	(1,344.62)	(467.70)
Purchase of shares by Employee Stock option trust	(353.39)	(96.41)
Interest paid	-	(3.33)
Payment of lease liabilities	(69.20)	(64.23)
<b>Net cash used in financing activities (c)</b>	<b>(1,767.21)</b>	<b>(631.67)</b>
<b>Net (decrease) in cash and cash equivalents (a) + (b) + (c)</b>	<b>(71.87)</b>	<b>(431.46)</b>
Cash and cash equivalents at the beginning of the year	290.51	722.06
Effect of exchange rate fluctuations on cash held	(0.02)	(0.09)
<b>Cash and cash equivalents at the end of the year</b>	<b>218.62</b>	<b>290.51</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	2.40	3.80
Bank balances	216.22	286.71
	<b>218.62</b>	<b>290.51</b>
<b>Cash and cash equivalents as per Statement of assets and liabilities</b>	<b>218.62</b>	<b>290.51</b>



**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Notes:**

- The above financial results for the quarter and year ended 31 March 2022 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 24 May 2022. The statutory auditors have audited the above results for the year ended 31 March 2022 and have issued an unmodified opinion.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Interim Dividend of INR 1/- per share, aggregating to INR. 292.31 Lakhs has been paid during the quarter ended 31 March 2022
- The figures for the quarters ended 31 March 2022 and 31 March 2021 are the balancing figures between audited figures in respect of the full financial years and published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review.
- The financial results of the Company for the Quarter/Year ended 31 March 2022 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com
- Segment reporting in the financial results:** Based on the 'management approach' as defined in Ind AS 108 "Operating Segments", the Chief Operating Decision Maker evaluates the Company's performance as OTC Products and Beverages.

(Rs.in Lakhs)

	Particulars	Quarter ended			Year ended	
		31 March 2022 (Audited - refer note 4)	31 December 2021 (Unaudited)	31 March 2021 (Audited - refer note 4)	31 March 2022 (Audited)	31 March 2021 (Audited)
<b>1</b>	<b>Segment revenue</b>					
a	OTC Products	9,407.10	10,648.32	8,497.01	37,221.24	31,426.35
b	Beverages	1,189.38	379.74	849.46	3,190.46	1,708.32
c	Others	58.82	41.53	55.21	172.54	149.73
	<b>Total</b>	<b>10,655.30</b>	<b>11,069.59</b>	<b>9,401.68</b>	<b>40,584.24</b>	<b>33,284.40</b>
<b>2</b>	<b>Segment results</b>					
a	OTC Products	2,007.32	2,581.91	1,373.34	8,288.14	7,868.78
b	Beverages	(93.19)	(35.05)	(64.35)	(7.09)	(350.16)
c	Others	(13.85)	(22.26)	(19.37)	(96.57)	(103.71)
	<b>Total</b>	<b>1,900.28</b>	<b>2,524.57</b>	<b>1,289.62</b>	<b>8,184.48</b>	<b>7,414.91</b>
	<b>Less :</b>					
i)	Finance cost	30.08	2.98	36.71	48.45	50.00
ii)	Other unallocable expenditure net of interest income	(131.73)	(269.91)	(118.24)	(921.63)	(825.54)
	<b>Total profit before tax</b>	<b>2,001.93</b>	<b>2,791.50</b>	<b>1,371.15</b>	<b>9,057.66</b>	<b>8,190.45</b>
<b>3</b>	<b>Segment assets</b>					
a	OTC Products	9,091.91	6,998.04	5,103.74	9,091.91	5,103.74
b	Beverages	2,073.42	1,876.82	910.23	2,073.42	910.23
c	Others	65.43	73.55	97.84	65.43	97.84
d	Unallocated assets	23,756.05	23,167.59	21,315.26	23,756.05	21,315.26
	<b>Total</b>	<b>34,986.81</b>	<b>32,116.00</b>	<b>27,427.07</b>	<b>34,986.81</b>	<b>27,427.07</b>
<b>4</b>	<b>Segment liabilities</b>					
a	OTC Products	5,492.11	5,310.12	4,362.76	5,492.11	4,362.76
b	Beverages	1,812.52	463.96	871.05	1,812.52	871.05
c	Others	68.28	70.84	94.73	68.28	94.73
d	Unallocated liabilities	1,101.52	711.75	542.06	1,101.52	542.06
	<b>Total</b>	<b>8,474.43</b>	<b>6,556.67</b>	<b>5,870.60</b>	<b>8,474.43</b>	<b>5,870.60</b>
	<b>Total capital employed in the Company</b>	<b>26,512.38</b>	<b>25,559.33</b>	<b>21,556.47</b>	<b>26,512.38</b>	<b>21,556.47</b>

For Amrutanjan Health Care Limited

  
**S Sambhu Prasad**  
Chairman & Managing Director

Date: 24 May 2022  
Place: Chennai

# B S R & Co. LLP

Chartered Accountants

KRM Tower, 1<sup>st</sup> & 2<sup>nd</sup> Floors,  
No. 1, Harrington Road, Chetpet,  
Chennai – 600 031, India

Telephone: +91 44 4608 3100  
Fax: +91 44 4608 3199

## Independent Auditor's Report

### To the Board of Directors of Amrutanjan Health Care Limited Report on the audit of the Annual Financial Results

#### Opinion

We have audited the accompanying annual financial results of Amrutanjan Health Care Limited (hereinafter referred to as the "Company") for the year ended 31 March 2022, attached herewith, (in which are included financial statement of an Employee Stock Option Plan ("ESOP trust")) being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report on audited financial statement of the ESOP trust the aforesaid annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2022.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of report of auditor of the ESOP trust referred to in the "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the annual financial results.

#### Management's and Board of Directors'/ Board of Trustees' Responsibilities for the Annual Financial Results

These annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the Company/Board of Trustees' of the ESOP trust are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company/ESOP trust and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and

Registered Office:

14th Floor, Central B Wing and North C Wing, NESCO IT Park 4, NESCO Center, Western Express Highway, Goregaon (East), Mumbai - 400063

**Independent Auditor's Report (Continued)**

**Amrutanjan Health Care Limited**

presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the respective Management and the Board of Directors/Board of Trustees are responsible for assessing the Company/ESOP trust to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/Board of Trustees either intends to liquidate the Company/Trust or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors/Board of Trustees are responsible for overseeing the financial reporting process of the Company/ESOP trust.

**Auditor's Responsibilities for the Audit of the Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial results, including the disclosures, and whether the annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements of the ESOP trust of the Company to express an opinion on the annual financial results. For the ESOP trust included in the annual financial results, which has been audited by auditor of ESOP trust, such auditor of ESOP trust remain responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in the "Other Matter" paragraph in this audit report.

**Independent Auditor's Report (Continued)**

**Amrutanjan Health Care Limited**

We communicate with those charged with governance of the Company and such other entity included in standalone annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

- a. The annual financial results include the audited financial statements of an ESOP trust, whose financial statements reflect total assets (before accounting adjustments) of Rs. 451.68 lakhs as at 31 March, 2022, total revenue (before accounting adjustments) of Rs. 0.94 lakhs and total net loss after tax (before accounting adjustments) of Rs. 33.05 lakhs for the year ended on that date as considered in the annual financial results, which has been audited by the auditor of the ESOP trust. The auditor's report on financial statements of the ESOP trust has been furnished to us by the management.

Our opinion on the annual financial results, in so far as it relates to the amounts and disclosures included in respect of the ESOP trust, is based solely on the report of such auditor.

Our opinion is not modified in respect of this matter.

- b. The annual financial results include the results for the quarter ended 31 March 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

  
K Raghuram  
Partner


Membership No.: 211171

UDIN:22211171AJNJQP3216

Chennai

24 May 2022





May 24, 2022

<b>The National Stock Exchange of India Limited</b> "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	<b>BSE Limited</b> Department of Corporate Services 1 <sup>st</sup> Floor, P.J. Towers, Dalal Street, Mumbai 400 001
<b>Symbol : AMRUTANJAN</b>	<b>Scrip Code: 590006</b>

Dear Sir / Madam,

**Sub: Declaration on Auditor's Report along with unmodified opinion under regulation 33 (3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

We, S. Sambhu Prasad, Chairman and Managing Director and N. Swaminathan, Chief Financial Officer of the Company "**Amrutanjan Health Care Limited**" (CIN: **L24231TN1936PLC000017**) hereby declare in terms of above said regulations as amended by SEBI (LODR) Amendment Regulations 2016 vide notification number **SEBI/LAD-NRO/GN-2016-17/001 dated May 25, 2016** and circular no **CIR/CFD/CMD/56/2016 dated May 27, 2016** that the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the quarter and year ended 31st March 2022.

Request you to take the same on record.

Yours Faithfully

For **Amrutanjan Health Care Limited**

S Sambhu Prasad  
Chairman & Managing Director

N. Swaminathan  
Chief Financial Officer.

**Amrutanjan Health Care Limited**

103, (Old No. 42-45), Luz Church Road,  
Mylapore, Chennai - 600 004  
Tamil Nadu, India.  
Tel : +91-44 - 2499 4465  
+91-44 - 2466 9000  
Fax : +91-44 - 2499 4585

E-mail : [customercare@amrutanjan.com](mailto:customercare@amrutanjan.com)  
Web Site : [www.amrutanjan.com](http://www.amrutanjan.com)  
Toll Free No. : 1 - 800 - 425 - 4545  
CIN - L24231TN1936PLC000017